[Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer].

Ge, R; Wang, B Y; Jiang, Z F

Ge, R; Wang, B Y; Jiang, Z F.

Afiliación

Ge R; Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China.
Wang BY; Department of Medical Oncology, Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China.
Jiang ZF; Department of Breast Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.

Zhonghua Zhong Liu Za Zhi ; 44(12): 1296-1304, 2022 Dec 23.

Article en Zh | MEDLINE | ID: mdl-36575782

Asunto(s)

Antineoplásicos; Neoplasias de la Mama; Inhibidores de Proteínas Quinasas; Femenino; Humanos; Aminopiridinas/efectos adversos; Antineoplásicos/efectos adversos; Neoplasias de la Mama/tratamiento farmacológico; Consenso; Quinasa 4 Dependiente de la Ciclina/antagonistas & inhibidores; Inhibidores de Proteínas Quinasas/efectos adversos; Quinasa 6 Dependiente de la Ciclina/antagonistas & inhibidores

Palabras clave

Adverse events; Breast neoplasms; CDK4/6 inhibitor; Expert consensus; Hormone receptor positive

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Inhibidores de Proteínas Quinasas / Antineoplásicos Tipo de estudio: Guideline Límite: Female / Humans Idioma: Zh Revista: Zhonghua Zhong Liu Za Zhi Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google